Great Bay Bio Adds Two Industry Leaders to Advisory Board

August 12, 2019 - 03:10
Great Bay Bio Adds Two Industry Leaders to Advisory Board

HONG KONG, CHINA - MediaOutReach - 12 August 2019 - Great Bay Bio, a leading AI biotechnology company dedicated to bigdata-driven CMC (Chemistry Manufacturing and Controls) development of innovativebiologics, is pleased to announce the establishment of its 3D Advisory Board.The board of directors eagerly welcome two top industry elites, Dr. Katie Suand Mr. Aaron Wang, to the company. They will cooperate with the board and advisethe senior management team on a range of company matters including, strategicpositioning, product portfolio composition, technical troubleshooting, and generalmanagement. More importantly, the 3D Advisory Board will bring a series offorward-looking concepts from both commercial and scientific arenas, to proposenew and efficient solutions to market problems. The establishment of the 3D AdvisoryBoard is of great significance to the company's value proposition. Great BayBio's mission is to "Face Future Challengeswith 3D Innovation". By combining three verticals of innovation "business foresight + science-basedfoundation + technology driven", new breakthroughs can be hatched. Currently,the company will form three separate sub-committees (Business, Science and Technology)to provide a solid foundation for Great Bay Bio's mission and, ultimately reachthe company's vision of "MakingBiologics Development Easy For Everyone".

BriefIntroduction of Members for Advisory Board

Dr. Katie (Jing)Su, who joins the Science Sub-Committee of the3D Advisory Board, has more than 20 years of management and operationexperience for novel drug research and development in the biopharmaceuticalindustry. She is currently serving as the President and Head of Novo NordiskR&D Center in China. Previously, she acted as the Chief Operating Officerof GlaxoSmithKline R&D Center in China. Dr. Su was responsible forformulating the development strategy and daily operation management of topresearch centers endorsed by different famous Pharmaceutical brands, workingclosely with the site leaders from various functions to drive businesspriorities. Earlier, Ms. Su led the establishment of a brand-new research unitof excellence in biologics discovery and engineering in Novo Nordisk China and attendedas the Head of the Department and Vice- President of global R&D. With hersolid scientific research capacity, she led the local team to excel in theglobal effort on clinical candidate development in metabolic diseases,hemophilia, autoimmune and cancer immunotherapy. At the same time, Dr. Su hasalso established the world's leading frontier platforms for identifying noveldrug targets and therapeutic candidates. Katie received a Bachelor Degree inMedicine, School of Medicine, Peking University, Beijing, China; a MasterDegree in Business Administration, Beijing International MBA Program (BiMBA),Peking University, China; a Doctorate Degree in Pharmacology, New YorkUniversity Medical Center, New York, US

Mr. Aaron(Yiran) Wang, who joins the Business Sub-Committee ofthe 3D Advisory Board, is currently an Investment Vice President in one of thetop venture capital funds in the world, primarily covering Greater China. Priorto his role in the fund, Mr. Wang was an entrepreneur, engineer and investorwith multinational working experience across Beijing and San Francisco Bay Area.He has obtained a Bachelor of Science degree in Electrical Engineering fromPeking University, a Master of Science degree in Electrical Engineering fromUniversity of Michigan-Ann Arbor and a Master of Business Administration degreefrom Harvard University.

On the establishment of the 3D Advisory Board andthe addition of the two industry elites, Mr.Kingsley Leung, Chairman and Co-founder of Great Bay Bio, said: "Thearrival of Dr. Su and Mr. Wang is undoubtedly one of the most importantmilestones of Great Bay Bio. I am very grateful and honored to have suchhigh-caliber and brilliant individuals become the first members of the AdvisoryBoard. One school of thought of innovation is Recombinant Innovation; the idea in which innovation breakthroughdoes not come from facile forms of creativity or out-of-the-box thinking, butfrom combining old ideas together to form new ones that fit the context ofneed. Actually many of today's innovation follows this school of thought, suchas the first smartphone; a combination of "older" innovation from differentfields and disciplines to form a world-changing device. We believe that thebest innovation comes from collaboration between people from differentbackgrounds and expertise, and this is why we have structured our AdvisoryBoard this way. The challenge of making traditional high-cost CMC cheap is a difficultone to solve, and that is why we believe Recombinant Innovation is our bestshot of tackling it."

About Great Bay Bio

Headquarteredin Hong Kong, the CMC/CDMO platform of Great Bay Bio was established in 2002,where originally more than 100 million yuan was invested to build a nationallevel CMC platform. The CMC/CDMO platform has independent and integrated technologyplatforms for drug R&D and large-scale preparation. The company has astrong existing track record of developing customized CMC packages for biologicproducts, some of which are national class I projects of innovative biological newdrugs that have already reached NDA stage.

Great Bay Biois leveraging on its established platform to develop a new vertical in CMC.Specifically, Great Bay Bio strives to utilize AI and other cutting-edgetechnologies to shorten CMC development timelines, lower cost, and increaseefficiency of CMC. With such a platform, it could expand and acquire newcustomer base, and brings fundamental changes to drug development, andultimately benefiting society and patients.

The platformhas been recognized and certificated as "Patent FosteringEnterprise", "Patent Pilot Enterprise", "National High-techEnterprise", "Dongguan New R&D Institution", "GuangdongTop Ten Foreign-funded R&D Center" and "Guangdong GeneticallyPharmaceutical Engineering Research Center". Since 2006, it has undertakena number of government projects and obtained crucial breakthroughs in key areasof Guangdong and Hong Kong. More than 20 million yuan have been received fromthe government to support numerous provincial and national projects, such as"National Major New Drug Innovation".

The CMC platformencompasses an area of over 3100 square meter, and has a whole set of advancedbiopharmaceutical research and development hardware, with key equipment from world-classbrands such as Sartorius, Bio-Rad, GE Healthcare, and Waters. The pilotworkshop is designed strictly in accordance with cGMP requirements, with cleanroomstandards of C-level and partial A-level.